Published in J Mol Biol on August 05, 1992
The membrane-proximal external region of the human immunodeficiency virus type 1 envelope: dominant site of antibody neutralization and target for vaccine design. Microbiol Mol Biol Rev (2008) 3.16
Rapid mapping of protein functional epitopes by combinatorial alanine scanning. Proc Natl Acad Sci U S A (2000) 2.24
Autoantigen discovery with a synthetic human peptidome. Nat Biotechnol (2011) 1.90
Site-directed mutagenesis studies of the high-affinity streptavidin-biotin complex: contributions of tryptophan residues 79, 108, and 120. Proc Natl Acad Sci U S A (1995) 1.89
Protein-protein interactions in eukaryotic transcription initiation: structure of the preinitiation complex. Proc Natl Acad Sci U S A (1996) 1.50
A functional epitope determinant on domain III of the Japanese encephalitis virus envelope protein interacted with neutralizing-antibody combining sites. J Virol (2003) 1.31
Association and dissociation kinetics of anti-hen egg lysozyme monoclonal antibodies HyHEL-5 and HyHEL-10. Biophys J (1998) 1.25
DNase I-hypersensitive sites I and II of the human growth hormone locus control region are a major developmental activator of somatotrope gene expression. Proc Natl Acad Sci U S A (1998) 1.13
Dissecting the energetics of an antibody-antigen interface by alanine shaving and molecular grafting. Protein Sci (1994) 1.13
Hydrogen/deuterium exchange mass spectrometry for probing higher order structure of protein therapeutics: methodology and applications. Drug Discov Today (2013) 1.13
Removal of B cell epitopes as a practical approach for reducing the immunogenicity of foreign protein-based therapeutics. Adv Drug Deliv Rev (2009) 1.07
Phage-displayed peptide libraries. Curr Opin Biotechnol (1998) 1.02
A sequential dimerization mechanism for erythropoietin receptor activation. Proc Natl Acad Sci U S A (1996) 0.99
Type 1 fimbrial adhesin FimH elicits an immune response that enhances cell adhesion of Escherichia coli. Infect Immun (2011) 0.99
Alternative views of functional protein binding epitopes obtained by combinatorial shotgun scanning mutagenesis. Protein Sci (2005) 0.94
Exploring peptide mimics for the production of antibodies against discontinuous protein epitopes. Mol Immunol (2009) 0.93
Identification of an immunodominant functional domain on human CD36 antigen using human-mouse chimaeric proteins and homologue-replacement mutagenesis. Biochem J (1995) 0.90
Stacking and energetic contribution of aromatic islands at the binding interface of antibody proteins. Immunome Res (2010) 0.89
Quantitative evaluation of the chicken lysozyme epitope in the HyHEL-10 Fab complex: free energies and kinetics. Protein Sci (1998) 0.88
Contributions of a highly conserved VH/VL hydrogen bonding interaction to scFv folding stability and refolding efficiency. Biophys J (1998) 0.88
The RafC1 cysteine-rich domain contains multiple distinct regulatory epitopes which control Ras-dependent Raf activation. Mol Cell Biol (1998) 0.87
Identification of conformational epitopes for human IgG on Chemotaxis inhibitory protein of Staphylococcus aureus. BMC Immunol (2009) 0.86
Structure from function: screening structural models with functional data. Proc Natl Acad Sci U S A (1994) 0.81
Mutational analysis of the major coat protein of M13 identifies residues that control protein display. Protein Sci (2000) 0.79
Mapping the epitopes of a neutralizing antibody fragment directed against the lethal factor of Bacillus anthracis and cross-reacting with the homologous edema factor. PLoS One (2013) 0.78
Mapping of Taenia solium TSOL18 antigenic epitopes by phage display library. Parasitol Res (2010) 0.77
Mapping the Energetic Epitope of an Antibody/Interleukin-23 Interaction with Hydrogen/Deuterium Exchange, Fast Photochemical Oxidation of Proteins Mass Spectrometry, and Alanine Shave Mutagenesis. Anal Chem (2017) 0.75
Several recombinant capsid proteins of equine rhinitis a virus show potential as diagnostic antigens. Clin Diagn Lab Immunol (2005) 0.75
Epitope mapping for the monoclonal antibody that inhibits intramolecular electron transfer in flavocytochrome b2. Biochem J (2003) 0.75
Complete mapping of viral escape from neutralizing antibodies. PLoS Pathog (2017) 0.75
A hot spot of binding energy in a hormone-receptor interface. Science (1995) 10.41
High-resolution epitope mapping of hGH-receptor interactions by alanine-scanning mutagenesis. Science (1989) 8.73
Convergent solutions to binding at a protein-protein interface. Science (2000) 4.47
Cloning, sequencing, and secretion of Bacillus amyloliquefaciens subtilisin in Bacillus subtilis. Nucleic Acids Res (1983) 3.70
p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor. Mol Cell Biol (1989) 3.62
Coexpression of erbB2 and erbB3 proteins reconstitutes a high affinity receptor for heregulin. J Biol Chem (1994) 3.46
Dimerization of the extracellular domain of the human growth hormone receptor by a single hormone molecule. Science (1991) 3.24
Dissecting the catalytic triad of a serine protease. Nature (1988) 3.19
In vitro selection of zinc fingers with altered DNA-binding specificity. Biochemistry (1994) 3.18
Comparison of a structural and a functional epitope. J Mol Biol (1993) 3.12
Systematic mutational analyses of protein-protein interfaces. Methods Enzymol (1991) 2.95
Phage display for selection of novel binding peptides. Methods Enzymol (2000) 2.78
Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). Semin Oncol (1999) 2.66
Site-directed ligand discovery. Proc Natl Acad Sci U S A (2000) 2.58
Rational design of potent antagonists to the human growth hormone receptor. Science (1992) 2.45
A systematic mutational analysis of hormone-binding determinants in the human growth hormone receptor. Proc Natl Acad Sci U S A (1991) 2.43
Crystal structure at 1.7 A resolution of VEGF in complex with domain 2 of the Flt-1 receptor. Cell (1997) 2.24
Cassette mutagenesis: an efficient method for generation of multiple mutations at defined sites. Gene (1985) 2.15
Structural plasticity in a remodeled protein-protein interface. Science (1997) 2.05
Substrate phage: selection of protease substrates by monovalent phage display. Science (1993) 2.04
Receptor and antibody epitopes in human growth hormone identified by homolog-scanning mutagenesis. Science (1989) 2.02
Mapping the CD4 binding site for human immunodeficiency virus by alanine-scanning mutagenesis. Proc Natl Acad Sci U S A (1990) 1.99
A second-generation study of 427 probands with congenital heart defects and their 837 children. J Am Coll Cardiol (1994) 1.97
Hormone phage: an enrichment method for variant proteins with altered binding properties. Proteins (1990) 1.94
Vascular endothelial growth factor: crystal structure and functional mapping of the kinase domain receptor binding site. Proc Natl Acad Sci U S A (1997) 1.91
Stimulation of human T-cell proliferation by specific activation of the 75-kDa tumor necrosis factor receptor. J Immunol (1993) 1.89
Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells. Oncogene (1994) 1.88
The prevalence of homosexual behavior and attraction in the United States, the United Kingdom and France: results of national population-based samples. Arch Sex Behav (1995) 1.86
The autocrine production of transforming growth factor-beta 1 during lymphocyte activation. A study with a monoclonal antibody-based ELISA. J Immunol (1990) 1.83
Monoclonal antibody (B27M2) subdividing HLA-B27. Hum Immunol (1982) 1.81
Structural and functional analysis of the 1:1 growth hormone:receptor complex reveals the molecular basis for receptor affinity. J Mol Biol (1998) 1.79
A designed peptide ligase for total synthesis of ribonuclease A with unnatural catalytic residues. Science (1994) 1.79
Minimizing a binding domain from protein A. Proc Natl Acad Sci U S A (1996) 1.75
Occupational stress and health among factory workers. J Health Soc Behav (1979) 1.72
Secretion and autoproteolytic maturation of subtilisin. Proc Natl Acad Sci U S A (1986) 1.72
In vitro selection from protein and peptide libraries. Trends Biotechnol (1994) 1.68
Engineering subtilisin and its substrates for efficient ligation of peptide bonds in aqueous solution. Biochemistry (1991) 1.66
Selecting high-affinity binding proteins by monovalent phage display. Biochemistry (1991) 1.66
Active site trapping of nucleotides by crosslinking two sulfhydryls in myosin subfragment 1. Proc Natl Acad Sci U S A (1979) 1.65
Humanization of an antibody directed against IgE. J Immunol (1993) 1.64
Zinc mediation of the binding of human growth hormone to the human prolactin receptor. Science (1990) 1.63
Recombinant tumor necrosis factor causes activation of human granulocytes. Blood (1987) 1.62
The fluorescent antibody tissue stain for Treponema pallidum in the eye. Am J Ophthalmol (1967) 1.59
Designing substrate specificity by protein engineering of electrostatic interactions. Proc Natl Acad Sci U S A (1987) 1.58
Monoclonal antibody therapy of human cancer: taking the HER2 protooncogene to the clinic. J Clin Immunol (1991) 1.57
Mutations of the growth hormone receptor in children with idiopathic short stature. The Growth Hormone Insensitivity Study Group. N Engl J Med (1995) 1.55
Requirements for binding and signaling of the kinase domain receptor for vascular endothelial growth factor. J Biol Chem (1998) 1.53
In vivo formation and stability of engineered disulfide bonds in subtilisin. J Biol Chem (1986) 1.51
Affinity maturation of human growth hormone by monovalent phage display. J Mol Biol (1993) 1.51
Bilateral macular drusen in age-related macular degeneration. Prognosis and risk factors. Ophthalmology (1994) 1.49
Engineering an enzyme by site-directed mutagenesis to be resistant to chemical oxidation. J Biol Chem (1985) 1.43
The human growth hormone receptor. Secretion from Escherichia coli and disulfide bonding pattern of the extracellular binding domain. J Biol Chem (1990) 1.43
Engineering enzyme specificity by "substrate-assisted catalysis". Science (1987) 1.43
Insulin responsiveness in skeletal muscle is determined by glucose transporter (Glut4) protein level. Biochem J (1990) 1.41
Subtilisin--an enzyme designed to be engineered. Trends Biochem Sci (1988) 1.40
Stable heterodimers from remodeling the domain interface of a homodimer using a phage display library. J Mol Biol (1997) 1.40
Probing steric and hydrophobic effects on enzyme-substrate interactions by protein engineering. Science (1986) 1.37
Expression of the p185 encoded by HER2 oncogene in normal and transformed human tissues. Int J Cancer (1990) 1.36
Subtiligase: a tool for semisynthesis of proteins. Proc Natl Acad Sci U S A (1994) 1.33
The role of lysine-234 in beta-lactamase catalysis probed by site-directed mutagenesis. Biochemistry (1990) 1.31
Recruitment of substrate-specificity properties from one enzyme into a related one by protein engineering. Proc Natl Acad Sci U S A (1987) 1.29
Long-term inhibition of tumor growth by tumor necrosis factor in the absence of cachexia or T-cell immunity. Proc Natl Acad Sci U S A (1991) 1.29
Mammalian cell transient expression of tissue factor for the production of antigen. Protein Eng (1990) 1.28
Growth regulation of human breast and ovarian tumor cells by heregulin: Evidence for the requirement of ErbB2 as a critical component in mediating heregulin responsiveness. Cancer Res (1996) 1.25
Structural mimicry of a native protein by a minimized binding domain. Proc Natl Acad Sci U S A (1997) 1.23
Rational design of receptor-specific variants of human growth hormone. Proc Natl Acad Sci U S A (1991) 1.21
A truncated intracellular HER2/neu receptor produced by alternative RNA processing affects growth of human carcinoma cells. Mol Cell Biol (1993) 1.20
Minimization of a polypeptide hormone. Science (1995) 1.19
Evidence for an autocrine role of activin B within rat anterior pituitary cultures. Endocrinology (1991) 1.19
Long-acting growth hormones produced by conjugation with polyethylene glycol. J Biol Chem (1996) 1.19
Novel peptides selected to bind vascular endothelial growth factor target the receptor-binding site. Biochemistry (1998) 1.19
Functional interaction among catalytic residues in subtilisin BPN'. Proteins (1990) 1.17
Dimerization of human growth hormone by zinc. Science (1991) 1.16
Strain specificity and binding affinity requirements of neutralizing monoclonal antibodies to the C4 domain of gp120 from human immunodeficiency virus type 1. J Virol (1993) 1.16
Antibody humanization using monovalent phage display. J Biol Chem (1997) 1.15
Chemical modification of myosin by active-site trapping of metal-nucleotides with thiol crosslinking reagents. Methods Enzymol (1982) 1.15
Protein engineering of disulfide bonds in subtilisin BPN'. Biochemistry (1989) 1.15
A survey of furin substrate specificity using substrate phage display. Protein Sci (1994) 1.13
Dissecting the energetics of an antibody-antigen interface by alanine shaving and molecular grafting. Protein Sci (1994) 1.13
Improvement in the alkaline stability of subtilisin using an efficient random mutagenesis and screening procedure. Protein Eng (1989) 1.13
Characterization of an anti-p185HER2 monoclonal antibody that stimulates receptor function and inhibits tumor cell growth. Growth Regul (1991) 1.13
Engineering human prolactin to bind to the human growth hormone receptor. Science (1990) 1.12
High copy display of large proteins on phage for functional selections. J Mol Biol (2000) 1.11
Monoclonal antibodies to the extracellular domain of HIV-1IIIB gp160 that neutralize infectivity, block binding to CD4, and react with diverse isolates. AIDS Res Hum Retroviruses (1992) 1.11
An improved method for purifying 2',5'-oligoadenylate synthetases. J Biol Chem (1984) 1.11
Minimized proteins. Curr Opin Struct Biol (1997) 1.11
Selection for improved subtiligases by phage display. Proc Natl Acad Sci U S A (1999) 1.10
Macular dystrophy associated with mutations at codon 172 in the human retinal degeneration slow gene. Ophthalmology (1994) 1.10
Probing the mechanism and improving the rate of substrate-assisted catalysis in subtilisin BPN'. Biochemistry (1991) 1.10
TGF-beta: a possible autocrine immune regulator. Ciba Found Symp (1991) 1.09
Designing subtilisin BPN' to cleave substrates containing dibasic residues. Biochemistry (1995) 1.08
Furilisin: a variant of subtilisin BPN' engineered for cleaving tribasic substrates. Biochemistry (1996) 1.07
Prolactin receptor antagonists that inhibit the growth of breast cancer cell lines. J Biol Chem (1995) 1.05
Structural and mutational analysis of affinity-inert contact residues at the growth hormone-receptor interface. Biochemistry (1996) 1.04
Binding interaction of the heregulinbeta egf domain with ErbB3 and ErbB4 receptors assessed by alanine scanning mutagenesis. J Biol Chem (1998) 1.03
Growth hormone augments superoxide anion secretion of human neutrophils by binding to the prolactin receptor. J Clin Invest (1992) 1.01
Mechanism-based design of prolactin receptor antagonists. J Biol Chem (1993) 1.00